Provided by Tiger Trade Technology Pte. Ltd.

BridgeBio Pharma, Inc.

76.59
-0.0100-0.01%
Post-market: 76.590.00000.00%19:41 EDT
Volume:2.06M
Turnover:157.22M
Market Cap:15.00B
PE:-21.46
High:77.24
Open:76.20
Low:75.02
Close:76.60
52wk High:93.42
52wk Low:48.78
Shares:195.81M
Float Shares:167.00M
Volume Ratio:1.42
T/O Rate:1.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5686
EPS(LYR):-3.7850
ROE:-1789.67%
ROA:-26.00%
PB:-5.96
PE(LYR):-20.24

Loading ...

BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 24

BridgeBio Oncology Therapeutics shareholders elect Lebowitz, McCormick to board

Reuters
·
Jun 23

Movement Alert|BridgeBio Pharma Rises 5.04% in Regular Trading, Trading at $69.625

Market Focus
·
Jun 23

BridgeBio to present Phase 3 PROPEL 3 trial results for oral infigratinib in children with achondroplasia at ICCBH 2026

Reuters
·
Jun 22

BridgeBio director Jennifer E. Cook disposes of common shares worth $6,011,959.36

Reuters
·
Jun 18

Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), BridgeBio Pharma (BBIO) and Guardant Health (GH)

TIPRANKS
·
Jun 17

BridgeBio Pharma Inc : Mizuho Cuts Target Price to $96 From $106

THOMSON REUTERS
·
Jun 16

U.S. RESEARCH ROUNDUP-CAMP4 Therapeutics, Rockwell Automation, Zions Bancorporation

Reuters
·
Jun 16

Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO) and BridgeBio Pharma (BBIO)

TIPRANKS
·
Jun 16

BRIEF-DKSH Enters Strategic Distribution Partnership With Bridgebio

Reuters
·
Jun 11

DKSH partners with BridgeBio to distribute ATTR-CM transthyretin stabilizer in Asia-Pacific markets

Reuters
·
Jun 11

BridgeBio CEO Neil Kumar reports $4.26 million common share disposal

Reuters
·
Jun 09

Barclays Sticks to Their Buy Rating for BridgeBio Pharma (BBIO)

TIPRANKS
·
Jun 05

How FDA Priority Review for First-in-Class LGMD Drug BBP-418 Could Impact BridgeBio Pharma (BBIO) Investors

Simply Wall St.
·
Jun 05

BridgeBio Pharma Inc : Canaccord Genuity Initiates Coverage With Buy Rating; Price Target $104

THOMSON REUTERS
·
Jun 03

Canaccord Genuity Initiates BridgeBio Pharma at Buy With $104 Price Target

MT Newswires Live
·
Jun 03

BridgeBio initiated with a Buy at Canaccord

TIPRANKS
·
Jun 03

BridgeBio publishes corporate presentation outlining rare-disease pipeline and 2026 milestones

Reuters
·
Jun 03

BridgeBio price target raised to $98 from $94 at Morgan Stanley

TIPRANKS
·
May 28

BridgeBio Pharma Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
May 28